The company experienced a significant setback with the deferral of its lead Phase 2a clinical trial due to negative regulatory feedback from MHRA. This delays the development timeline for its primary influenza candidate and raises questions about the compound's regulatory viability, despite management's assertion that backup candidates are being advanced.
Also mentions TRAW
Articles that tag TRAW but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
